The purpose of this study is to assess the safety and efficacy of LY2140023 (flexibly dosed between 20 and 80 mg BID) in patients with schizophrenia. An active control, aripiprazole (flexibly dosed between 10 and 30 mg/day), is included for comparison. The primary outcome measure will be mean weight change.
Who may be Eligible
Male or female 18 to 65 with a diagnosis of Schizophrenia.
Speciality/Disorder
Schizophrenia
IRB Number
CHS1-11-094
Principal Investigator
Tcheremissine, Oleg
For More Information, Contact Dineen , Gardner
Phone: (704) 446-7511 Fax: (704) 446-7506 Email: dineen.gardner@atriumhealth.org Address:465 North Wendover Road Charlotte, NC 28211